Wasdell Group in December 2017 announced the investment of €30m ($33.64) to build the new EU headquarters, and work began on the facility in September 2018.
A successful Health Products Regulatory Authority (HPRA) inspection was conducted in late 2018 at the location, enabling Wasdell to perform QP batch certification and release of pharmaceutical products into Europe, as part of its Brexit preparations.
The 90,000 square foot facility, located in the new IDA Technology and Science Park, features 11 production suites and temperature controlled high-bay warehouses.
According to the company, the facility boosts its capacity in clinical and commercial packaging, distribution and logistics, as well as qualified persons (QP) services.
Vincent Dunne, CEO said: “We are seeing growing demand for our services, especially from companies that wish to outsource their entire product lifecycle from clinical services and EU launch to manufacturing, packaging and distribution. The new facility strengthens our offering, allowing us to further support our customers.”
“With over 75% of our turnover as export business, our new facility will serve our large client base in Europe and better support our growing US customer portfolio as they look to outsource their European supply chain operations from clinical projects to routine supply,” he added.
